CHI3L1 and neoplasm: In line with these findings, treating U87 tumor-bearing mice with a neutralizing anti-YKL-40 antibody (mAY) resulted in abrogation of tumor angiogenesis, reduced distant metastasis, and increased mouse survival [27, 40], all of which underscore an angiogenic signature of YKL-40 in tumor progression.